Factors predicting use of neoadjuvant chemotherapy compared with primary debulking surgery in advanced stage ovarian cancer - A national cancer database study

Gary S. Leiserowitz, Jeff F. Lin, Ana I. Tergas, William Arthur Cliby, Robert E. Bristow

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objectives: We performed a patterns-of-care study to characterize the types of patients with epithelial ovarian cancer (EOC) who received neoadjuvant chemotherapy (NACT) versus primary debulking surgery (PDS) using the National Cancer Database (NCDB). Methods: We identified patients with stages IIIC and IV EOC in the NCDB diagnosed from 2003 to 2011. Patients who received chemotherapy (CT) prior to surgery were classified as receiving NACT; if surgery preceded CT, then it was classified as PDS. Data collected from the NCDB included demographics, medical comorbidity index, cancer characteristics and treatment, and hospital characteristics. Univariate and multivariable analyses were performed using W2 test, logistic regression, log-rank test, and Cox proportional hazards modeling as indicated. Statistical significance was set at P G 0.05. Results: A total of 62,727 patients with stages IIIC and IV EOC were identified. The sequence of surgery and CT was identified, of which 6922 (11%) had NACT and 31,280 (50%) had PDS. Neoadjuvant CT was more frequently done in stage IV than stage IIIC (13% vs 9%), and its use markedly increased over time. Variables associated with increased likelihood of NACT use were as follows: age older than 50 years and those with higher comorbidities, stage IV, and higher-grade EOC. Neoadjuvant CT use was also associated with hospitals that were adherent to the National Comprehensive Cancer Network guidelines, high-volume facilities, those in the Midwest and West, and academic centers. Conclusions: Evidence suggests that patients with greater adverse risk factors are more likely to receive NACT instead of PDS. Use of NACT has significantly increased over the study period, especially in patients with stage IV ovarian cancer.

Original languageEnglish (US)
Pages (from-to)675-683
Number of pages9
JournalInternational Journal of Gynecological Cancer
Volume27
Issue number4
DOIs
StatePublished - 2017

Fingerprint

Ovarian Neoplasms
Databases
Drug Therapy
Neoplasms
Comorbidity
Logistic Models
Demography
Guidelines
Ovarian epithelial cancer

Keywords

  • Neoadjuvant chemotherapy
  • Ovarian cancer
  • Patterns of care

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Factors predicting use of neoadjuvant chemotherapy compared with primary debulking surgery in advanced stage ovarian cancer - A national cancer database study. / Leiserowitz, Gary S.; Lin, Jeff F.; Tergas, Ana I.; Cliby, William Arthur; Bristow, Robert E.

In: International Journal of Gynecological Cancer, Vol. 27, No. 4, 2017, p. 675-683.

Research output: Contribution to journalArticle

@article{8d8ec37dd2cf4e22bfa48280c338ddb3,
title = "Factors predicting use of neoadjuvant chemotherapy compared with primary debulking surgery in advanced stage ovarian cancer - A national cancer database study",
abstract = "Objectives: We performed a patterns-of-care study to characterize the types of patients with epithelial ovarian cancer (EOC) who received neoadjuvant chemotherapy (NACT) versus primary debulking surgery (PDS) using the National Cancer Database (NCDB). Methods: We identified patients with stages IIIC and IV EOC in the NCDB diagnosed from 2003 to 2011. Patients who received chemotherapy (CT) prior to surgery were classified as receiving NACT; if surgery preceded CT, then it was classified as PDS. Data collected from the NCDB included demographics, medical comorbidity index, cancer characteristics and treatment, and hospital characteristics. Univariate and multivariable analyses were performed using W2 test, logistic regression, log-rank test, and Cox proportional hazards modeling as indicated. Statistical significance was set at P G 0.05. Results: A total of 62,727 patients with stages IIIC and IV EOC were identified. The sequence of surgery and CT was identified, of which 6922 (11{\%}) had NACT and 31,280 (50{\%}) had PDS. Neoadjuvant CT was more frequently done in stage IV than stage IIIC (13{\%} vs 9{\%}), and its use markedly increased over time. Variables associated with increased likelihood of NACT use were as follows: age older than 50 years and those with higher comorbidities, stage IV, and higher-grade EOC. Neoadjuvant CT use was also associated with hospitals that were adherent to the National Comprehensive Cancer Network guidelines, high-volume facilities, those in the Midwest and West, and academic centers. Conclusions: Evidence suggests that patients with greater adverse risk factors are more likely to receive NACT instead of PDS. Use of NACT has significantly increased over the study period, especially in patients with stage IV ovarian cancer.",
keywords = "Neoadjuvant chemotherapy, Ovarian cancer, Patterns of care",
author = "Leiserowitz, {Gary S.} and Lin, {Jeff F.} and Tergas, {Ana I.} and Cliby, {William Arthur} and Bristow, {Robert E.}",
year = "2017",
doi = "10.1097/IGC.0000000000000967",
language = "English (US)",
volume = "27",
pages = "675--683",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Wolters Kluwer Health",
number = "4",

}

TY - JOUR

T1 - Factors predicting use of neoadjuvant chemotherapy compared with primary debulking surgery in advanced stage ovarian cancer - A national cancer database study

AU - Leiserowitz, Gary S.

AU - Lin, Jeff F.

AU - Tergas, Ana I.

AU - Cliby, William Arthur

AU - Bristow, Robert E.

PY - 2017

Y1 - 2017

N2 - Objectives: We performed a patterns-of-care study to characterize the types of patients with epithelial ovarian cancer (EOC) who received neoadjuvant chemotherapy (NACT) versus primary debulking surgery (PDS) using the National Cancer Database (NCDB). Methods: We identified patients with stages IIIC and IV EOC in the NCDB diagnosed from 2003 to 2011. Patients who received chemotherapy (CT) prior to surgery were classified as receiving NACT; if surgery preceded CT, then it was classified as PDS. Data collected from the NCDB included demographics, medical comorbidity index, cancer characteristics and treatment, and hospital characteristics. Univariate and multivariable analyses were performed using W2 test, logistic regression, log-rank test, and Cox proportional hazards modeling as indicated. Statistical significance was set at P G 0.05. Results: A total of 62,727 patients with stages IIIC and IV EOC were identified. The sequence of surgery and CT was identified, of which 6922 (11%) had NACT and 31,280 (50%) had PDS. Neoadjuvant CT was more frequently done in stage IV than stage IIIC (13% vs 9%), and its use markedly increased over time. Variables associated with increased likelihood of NACT use were as follows: age older than 50 years and those with higher comorbidities, stage IV, and higher-grade EOC. Neoadjuvant CT use was also associated with hospitals that were adherent to the National Comprehensive Cancer Network guidelines, high-volume facilities, those in the Midwest and West, and academic centers. Conclusions: Evidence suggests that patients with greater adverse risk factors are more likely to receive NACT instead of PDS. Use of NACT has significantly increased over the study period, especially in patients with stage IV ovarian cancer.

AB - Objectives: We performed a patterns-of-care study to characterize the types of patients with epithelial ovarian cancer (EOC) who received neoadjuvant chemotherapy (NACT) versus primary debulking surgery (PDS) using the National Cancer Database (NCDB). Methods: We identified patients with stages IIIC and IV EOC in the NCDB diagnosed from 2003 to 2011. Patients who received chemotherapy (CT) prior to surgery were classified as receiving NACT; if surgery preceded CT, then it was classified as PDS. Data collected from the NCDB included demographics, medical comorbidity index, cancer characteristics and treatment, and hospital characteristics. Univariate and multivariable analyses were performed using W2 test, logistic regression, log-rank test, and Cox proportional hazards modeling as indicated. Statistical significance was set at P G 0.05. Results: A total of 62,727 patients with stages IIIC and IV EOC were identified. The sequence of surgery and CT was identified, of which 6922 (11%) had NACT and 31,280 (50%) had PDS. Neoadjuvant CT was more frequently done in stage IV than stage IIIC (13% vs 9%), and its use markedly increased over time. Variables associated with increased likelihood of NACT use were as follows: age older than 50 years and those with higher comorbidities, stage IV, and higher-grade EOC. Neoadjuvant CT use was also associated with hospitals that were adherent to the National Comprehensive Cancer Network guidelines, high-volume facilities, those in the Midwest and West, and academic centers. Conclusions: Evidence suggests that patients with greater adverse risk factors are more likely to receive NACT instead of PDS. Use of NACT has significantly increased over the study period, especially in patients with stage IV ovarian cancer.

KW - Neoadjuvant chemotherapy

KW - Ovarian cancer

KW - Patterns of care

UR - http://www.scopus.com/inward/record.url?scp=85020297273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020297273&partnerID=8YFLogxK

U2 - 10.1097/IGC.0000000000000967

DO - 10.1097/IGC.0000000000000967

M3 - Article

VL - 27

SP - 675

EP - 683

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 4

ER -